NEW YORK, July 25, 2018 /PRNewswire/ --
If you want a free Stock Review on AGEN, AIMT, AKBA,
and ALDR sign up now at
https://stocktraderreport.com/registration/. On Tuesday, key US
indices were mixed as the NASDAQ Composite finished the trading
session down 0.01%; the Dow Jones Industrial Average edged 0.79%
higher; and the S&P 500 was up 0.48%. Before the US markets
open this morning, StockTraderReport.com appraises these four
Biotechnology equities: Agenus Inc. (NASDAQ: AGEN), Aimmune
Therapeutics Inc. (NASDAQ: AIMT), Akebia Therapeutics Inc. (NASDAQ:
AKBA), and Alder Biopharmaceuticals Inc. (NASDAQ: ALDR). All you
have to do is sign up today for this free limited time offer by
clicking the link below.
https://stocktraderreport.com/registration/
Agenus
USA-headquartered Agenus Inc.'s
stock finished Tuesday's session 5.83% lower at $1.94. A total volume of 2.62 million shares was
traded, which was above its three months average volume of 1.43
million shares. The stock is trading below its 50-day moving
average by 30.38%. Furthermore, shares of Agenus, which focuses on
the discovery and development of therapies that engage the body's
immune system to fight cancer, have a Relative Strength Index (RSI)
of 27.84.
On July 16th, 2018,
Agenus announced the appointment of I-O drug development experts
into key leadership positions to advance multiple clinical programs
and planned BLA filings by 2020. Dr. Sunil Gupta joins
the Company as Vice President of Regulatory and Pharmacovigilance,
and Dr. Anna Wijatyk joins as Vice President of Clinical
Development. Get the full research report on AGEN for free by
clicking below at:
https://stocktraderreport.com/registration/?symbol=AGEN
Aimmune Therapeutics
Shares in USA-based Aimmune Therapeutics Inc. ended at
$29.72, up 0.71% from the last
trading session. The stock recorded a trading volume of 407,249
shares. The Company's shares have gained 35.09% in the last twelve
months. The stock is trading below its 50-day moving average by
0.80%. Moreover, shares of Aimmune Therapeutics, which develops and
commercializes product candidates for the treatment of peanut and
other food allergies, have an RSI of 53.01. To experience our free
membership services anytime/ anywhere and access the free report on
AIMT, click to register at:
https://stocktraderreport.com/registration/?symbol=AIMT
Akebia Therapeutics
USA-based Akebia Therapeutics
Inc.'s stock ended yesterday's session 1.74% higher at $10.51 with a total trading volume of 540,772
shares, which was above its three months average volume of 532.94
thousand shares. The Company's shares have advanced 12.29% over the
previous three months. The stock is trading above its 50-day moving
average by 2.11%. Additionally, shares of Akebia Therapeutics,
which focuses on the development and commercialization of novel
therapeutics for patients with renal disease through
hypoxia-inducible factor biology, have an RSI of 54.43.
On July 02nd, 2018,
Akebia Therapeutics (AKBA) announced that it granted six,
newly-hired employees options to purchase an aggregate of 12,050
shares of its common stock on June
29th, 2018, as inducements material to each such
employee's entering into employment with AKBA. The options were
granted in accordance with NASDAQ Listing Rule 5635(c)(4). Join our
big investor community at Stock Trader Report now and get your free
report on AKBA at:
https://stocktraderreport.com/registration/?symbol=AKBA
Alder Biopharmaceuticals
On Tuesday, shares in USA-headquartered Alder Biopharmaceuticals
Inc. recorded a trading volume of 740,547 shares. The stock
finished the day 2.16% lower at $18.10. The Company's shares have advanced 38.70%
in the previous three months, 52.10% over the last twelve months,
and 58.08% since the start of this year. The stock is trading above
its 50-day and 200-day moving averages by 7.10% and 29.69%,
respectively. Furthermore, shares of Alder Biopharma, which
operates as a clinical-stage biopharmaceutical company, have an RSI
of 54.90.
On June 27th, 2018,
research firm Needham resumed its 'Buy' rating on the Company's
stock, with a target price of $28 per
share.
On June 29th, 2018,
Alder Biopharma announced new, one-year efficacy data from the
PROMISE 1 Phase-3 clinical trial in patients with episodic
migraine. The data demonstrate that patients experienced even
further reductions in monthly migraine days following the third and
fourth quarterly infusions of eptinezumab, the Company's lead
investigational product candidate for migraine prevention targeting
calcitonin gene-related peptide. Know more about ALDR in our free
research coverage at:
https://stocktraderreport.com/registration/?symbol=ALDR
--
Stock Trader Report:
Stock Trader Report (STR) produces regular sponsored and
non-sponsored reports, articles, stock market blogs, and popular
investment newsletters covering equities listed on NYSE and NASDAQ
and micro-cap stocks. STR has two distinct and independent
departments. One department produces non-sponsored analyst
certified content generally in the form of press releases, articles
and reports covering equities listed on NYSE and NASDAQ and the
other produces sponsored content (in most cases not reviewed by a
registered analyst), which typically consists of compensated
investment newsletters, articles and reports covering listed stocks
and micro-caps. Such sponsored content is outside the scope of
procedures detailed below.
STR has not been compensated; directly or indirectly; for
producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by
a writer (the "Author") and is fact checked and reviewed by a
third-party research service company (the "Reviewer") represented
by a credentialed financial analyst [for further information on
analyst credentials, please email info@stocktraderreport.com .
Rohit Tuli, a CFA® charterholder
(the "Sponsor"), provides necessary guidance in preparing the
document templates. The Reviewer has reviewed and revised the
content, as necessary, based on publicly available information
which is believed to be reliable. Content is researched, written
and reviewed on a reasonable-effort basis. The Reviewer has not
performed any independent investigations or forensic audits to
validate the information herein. The Reviewer has only
independently reviewed the information provided by the Author
according to the procedures outlined by STR. STR is not entitled to
veto or interfere in the application of such procedures by the
third-party research service company to the articles, documents or
reports, as the case may be. Unless otherwise noted, any content
outside of this document has no association with the Author or the
Reviewer in any way.
NO WARRANTY
STR, the Author, and the Reviewer are not responsible for any
error which may be occasioned at the time of printing of this
document or any error, mistake or shortcoming. No liability is
accepted whatsoever for any direct, indirect or consequential loss
arising from the use of this document. STR, the Author, and the
Reviewer expressly disclaim any fiduciary responsibility or
liability for any consequences, financial or otherwise arising from
any reliance placed on the information in this document.
Additionally, STR, the Author, and the Reviewer do not (1)
guarantee the accuracy, timeliness, completeness or correct
sequencing of the information, or (2) warrant any results from use
of the information. The included information is subject to change
without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or
a solicitation of an offer to buy or sell the securities mentioned
or discussed, and is to be used for informational purposes only.
Please read all associated disclosures and disclaimers in full
before investing. Neither STR nor any party affiliated with us is a
registered investment adviser or broker-dealer with any agency or
in any jurisdiction whatsoever. To download our report(s), read our
disclosures, or for more information, visit
https://stocktraderreport.com/privacy-policy/
CONTACT
For any questions, inquiries, or comments reach out to us directly.
If you're a company, we are
covering and wish to no longer feature on our coverage list contact
us via email and/or phone between 09:30 EDT
to 16:00 EDT from Monday to Friday at:
Email: info@stocktraderreport.com
Phone number: 917-979-2038
Office Address: 22/F. 3 Lockhart Road, Wanchai Hong Kong
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE Stock Trader Report